Avapritinib 100mg
| Product Overview | |
| Generic Name | Avapritinib 100mg |
| Brand Name(s) | Ayvakit® |
| Form | 30 Film-coated tablets; oral use |
| Strength | 25 mg; 50 mg; 100 mg; 200 mg; 300 mg |
| Therapeutic Class | Antineoplastic agent; kinase inhibitor |
| ATC Code | L01EX18 |
| Manufacturing & Regulatory | |
| Manufacturer | Blueprint Medicines Corporation |
| Country | USA |
| GMP Compliance | WHO-GMP |
| COFEPRIS | No confirmed COFEPRIS clave |
| Free Sale Certificate | available only through the marketing authorisation holder or authorised distributor |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 48 Months |
| Storage | store at 20°C to 25°C |
| Incoterms | Ex-Works |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | only through authorised manufacturer/distributor channels. |
| CTD Summary | Full CTD/eCTD Modules 2–5 are proprietary and not publicly released. |
Description
an oral targeted kinase inhibitor used in adults with unresectable or metastatic gastrointestinal stromal tumor harboring PDGFRA exon 18 mutations, including D842V, Development code: BLU-285. CAS: 1703793-34-3
